BR112019016672A8 - Método para gerar progenitores de células t - Google Patents
Método para gerar progenitores de células tInfo
- Publication number
- BR112019016672A8 BR112019016672A8 BR112019016672A BR112019016672A BR112019016672A8 BR 112019016672 A8 BR112019016672 A8 BR 112019016672A8 BR 112019016672 A BR112019016672 A BR 112019016672A BR 112019016672 A BR112019016672 A BR 112019016672A BR 112019016672 A8 BR112019016672 A8 BR 112019016672A8
- Authority
- BR
- Brazil
- Prior art keywords
- cell progenitors
- generate
- stemregenin
- dioxin
- cultivating
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract 1
- BGFHMYJZJZLMHW-UHFFFAOYSA-N 4-[2-[[2-(1-benzothiophen-3-yl)-9-propan-2-ylpurin-6-yl]amino]ethyl]phenol Chemical compound N1=C(C=2C3=CC=CC=C3SC=2)N=C2N(C(C)C)C=NC2=C1NCCC1=CC=C(O)C=C1 BGFHMYJZJZLMHW-UHFFFAOYSA-N 0.000 abstract 1
- 239000004215 Carbon black (E152) Substances 0.000 abstract 1
- -1 Dioxin hydrocarbon Chemical class 0.000 abstract 1
- 102000016359 Fibronectins Human genes 0.000 abstract 1
- 108010067306 Fibronectins Proteins 0.000 abstract 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 abstract 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 229930195733 hydrocarbon Natural products 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/145—Thrombopoietin [TPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/25—Tumour necrosing factors [TNF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/42—Notch; Delta; Jagged; Serrate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/52—Fibronectin; Laminin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17305161 | 2017-02-13 | ||
| PCT/EP2018/053406 WO2018146297A1 (en) | 2017-02-13 | 2018-02-12 | Method for generating t cells progenitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112019016672A2 BR112019016672A2 (pt) | 2020-04-14 |
| BR112019016672A8 true BR112019016672A8 (pt) | 2022-11-22 |
Family
ID=58185453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019016672A BR112019016672A8 (pt) | 2017-02-13 | 2018-02-12 | Método para gerar progenitores de células t |
Country Status (17)
| Country | Link |
|---|---|
| US (5) | US20200046767A1 (enExample) |
| EP (2) | EP4067482A1 (enExample) |
| JP (2) | JP7164798B2 (enExample) |
| KR (1) | KR102666158B1 (enExample) |
| CN (1) | CN110506110B (enExample) |
| AU (1) | AU2018217404B2 (enExample) |
| BR (1) | BR112019016672A8 (enExample) |
| CA (1) | CA3053294A1 (enExample) |
| DK (1) | DK3580330T3 (enExample) |
| ES (1) | ES2931530T3 (enExample) |
| HU (1) | HUE060548T2 (enExample) |
| IL (1) | IL268641B2 (enExample) |
| MA (1) | MA47541A (enExample) |
| PL (1) | PL3580330T3 (enExample) |
| PT (1) | PT3580330T (enExample) |
| WO (1) | WO2018146297A1 (enExample) |
| ZA (1) | ZA201905470B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018217404B2 (en) * | 2017-02-13 | 2024-03-28 | Assistance Publique - Hopitaux De Paris | Method for generating T cells progenitors |
| WO2019067811A1 (en) * | 2017-09-29 | 2019-04-04 | Regents Of The University Of Minnesota | METHODS OF MANUFACTURING, EXPANDING AND USING HUMAN PROGENITOR CELL |
| EP3752602A4 (en) | 2018-02-14 | 2021-11-24 | Sunnybrook Research Institute | T-LYMPHOCYTE LINE CELL GENERATION PROCESS |
| WO2020051453A1 (en) * | 2018-09-07 | 2020-03-12 | Wisconsin Alumni Research Foundation | Generation of hematopoietic progenitor cells from human pluripotent stem cells |
| WO2020223517A1 (en) * | 2019-05-01 | 2020-11-05 | Transfusion Health, Llc | Methods of making oligopotent and unipotent precursors |
| WO2020264019A1 (en) * | 2019-06-24 | 2020-12-30 | Children's Hospital Los Angeles | Bcl11b overexpression to enhance human thymopoiesis and t cell function |
| CA3159629A1 (en) * | 2019-11-14 | 2021-05-20 | Peter William ZANDSTRA | Media formulations and methods for producing progenitor t cells |
| JPWO2021200901A1 (enExample) * | 2020-03-31 | 2021-10-07 | ||
| EP4251651A4 (en) | 2020-11-30 | 2025-07-09 | Cho Pharma Inc | ANTIBODIES FOR CELL ENRICHMENT |
| WO2022248354A1 (en) * | 2021-05-25 | 2022-12-01 | Universiteit Gent | Generating t cell precursors via agonizing tumor necrosis factor receptor 2 |
| JP2024542151A (ja) | 2021-11-04 | 2024-11-13 | エーピーエイチピー（アシスタンス パブリック－オピトークス ド パリ） | Ｎｋ細胞の生成法 |
| FR3130843A1 (fr) * | 2021-12-21 | 2023-06-23 | Universite Claude Bernard Lyon 1 | Cellule progéniteur des lymphocytes T exprimant de manière régulée un transgène d’intérêt |
| WO2024156066A1 (en) | 2023-01-27 | 2024-08-02 | Notch Therapeutics (Canada), Inc. | Method for generating t cell lineage populations from stem/progenitor cells |
| KR20250152088A (ko) * | 2023-02-22 | 2025-10-22 | 메이라지티엑스 셀 테라피스 | 흉선 재생 방법 |
| US20250332260A1 (en) | 2024-04-10 | 2025-10-30 | Garuda Therapeutics, Inc. | Immune compatible cells for allogeneic cell therapies to cover global, ethnic, or disease-specific populations |
| WO2025219552A1 (en) | 2024-04-17 | 2025-10-23 | Assitance Publique Hopitaux De Paris | Method for producing t cell progenitors from human pluripotent stem cells |
| CN119709836B (zh) * | 2024-12-21 | 2025-08-08 | 湖南农业大学 | OsProT2基因在调控水稻镉含量、镉耐受性及产量中的应用和方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6093531A (en) | 1997-09-29 | 2000-07-25 | Neurospheres Holdings Ltd. | Generation of hematopoietic cells from multipotent neural stem cells |
| AU753975B2 (en) | 1997-12-04 | 2002-10-31 | Duke University | Methods of isolating and using CD7+CD34-Lin-hematopoietic cells |
| US10059923B2 (en) | 2008-01-30 | 2018-08-28 | Memorial Sloan Kettering Cancer Center | Methods for off-the-shelf tumor immunotherapy using allogeneic T-cell precursors |
| RU2535966C2 (ru) | 2008-09-12 | 2014-12-20 | Криопрашис Криобиоложия Лтда. | Клеточная терапия ишемической ткани |
| AU2009311232B2 (en) * | 2008-11-07 | 2014-10-30 | Sunnybrook Health Sciences Centre | Human progenitor T-cells |
| US8871510B2 (en) | 2009-12-03 | 2014-10-28 | University Of Utah Research Foundation | Methods for generating T lymphocytes from hematopoietic stem cells |
| WO2011127470A1 (en) | 2010-04-09 | 2011-10-13 | Fred Hutchinson Cancer Research Center | Compositions and methods for providing hematopoietic function without hla matching |
| US10391126B2 (en) | 2011-11-18 | 2019-08-27 | Board Of Regents, The University Of Texas System | CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA |
| EP2788476B1 (en) * | 2011-12-08 | 2019-05-22 | Fred Hutchinson Cancer Research Center | Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells |
| WO2014110353A1 (en) | 2013-01-11 | 2014-07-17 | The Trustees Of The University Of Pennsylvania | Notch ligand bound bicompatible substrates and their use in bone formation |
| AU2014296059B2 (en) | 2013-08-02 | 2020-12-10 | The Regents Of The University Of California | Engineering antiviral T cell immunity through stem cells and chimeric antigen receptors |
| US20170128556A1 (en) | 2013-12-26 | 2017-05-11 | Thyas Co. Ltd. | Immunotherapy using t precursor cells derived from pluripotent stem cells having rearranged t cell receptor genes |
| US20170158749A1 (en) | 2014-04-23 | 2017-06-08 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors (car) and methods for making and using the same |
| CA2946222C (en) * | 2014-04-24 | 2020-12-22 | Miltenyi Biotec Gmbh | Method for automated generation of genetically modified t cells |
| EP3191596B1 (en) | 2014-09-11 | 2019-10-09 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Lentiviral vector for treating hemoglobin disorders |
| FR3026744B1 (fr) * | 2014-10-06 | 2024-04-19 | Hopitaux Paris Assist Publique | Methode de generation de progeniteurs de cellules t |
| CA2989858A1 (en) * | 2015-06-17 | 2016-12-22 | The Uab Research Foundation | Crispr/cas9 complex for introducing a functional polypeptide into cells of blood cell lineage |
| JP7049261B2 (ja) | 2016-04-08 | 2022-04-06 | ザ ガバニング カウンシル オブ ザ ユニバーシティ オブ トロント | 幹細胞および／または前駆細胞からｔ前駆細胞を作製する方法ならびに該ｔ前駆細胞の使用 |
| AU2018217404B2 (en) * | 2017-02-13 | 2024-03-28 | Assistance Publique - Hopitaux De Paris | Method for generating T cells progenitors |
-
2018
- 2018-02-12 AU AU2018217404A patent/AU2018217404B2/en active Active
- 2018-02-12 EP EP22158116.8A patent/EP4067482A1/en active Pending
- 2018-02-12 DK DK18704551.3T patent/DK3580330T3/da active
- 2018-02-12 IL IL268641A patent/IL268641B2/en unknown
- 2018-02-12 CA CA3053294A patent/CA3053294A1/en active Pending
- 2018-02-12 HU HUE18704551A patent/HUE060548T2/hu unknown
- 2018-02-12 CN CN201880024963.1A patent/CN110506110B/zh active Active
- 2018-02-12 US US16/485,488 patent/US20200046767A1/en not_active Abandoned
- 2018-02-12 KR KR1020197024529A patent/KR102666158B1/ko active Active
- 2018-02-12 MA MA047541A patent/MA47541A/fr unknown
- 2018-02-12 ES ES18704551T patent/ES2931530T3/es active Active
- 2018-02-12 EP EP18704551.3A patent/EP3580330B1/en active Active
- 2018-02-12 PL PL18704551.3T patent/PL3580330T3/pl unknown
- 2018-02-12 PT PT187045513T patent/PT3580330T/pt unknown
- 2018-02-12 BR BR112019016672A patent/BR112019016672A8/pt unknown
- 2018-02-12 JP JP2019565052A patent/JP7164798B2/ja active Active
- 2018-02-12 WO PCT/EP2018/053406 patent/WO2018146297A1/en not_active Ceased
-
2019
- 2019-08-19 ZA ZA2019/05470A patent/ZA201905470B/en unknown
-
2020
- 2020-09-02 US US17/010,208 patent/US11426430B2/en active Active
-
2021
- 2021-02-11 US US17/173,632 patent/US11638723B2/en active Active
- 2021-02-11 US US17/173,668 patent/US11642376B2/en active Active
-
2022
- 2022-09-28 JP JP2022154550A patent/JP2022185024A/ja active Pending
-
2023
- 2023-04-06 US US18/296,623 patent/US20230293586A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019016672A8 (pt) | Método para gerar progenitores de células t | |
| MX392031B (es) | Compuestos y métodos para modular la cinasa de linfocitos t inducible por interleucina 2 | |
| MY189778A (en) | Method for producing retinal pigment epithelial cells | |
| CL2016002010A1 (es) | Métodos y sistemas para generar mapas colaborativos compartidos | |
| SA517381666B1 (ar) | B مستقبلات مولد ضد خيمري تستهدف مولد ضد نضج الخلايا | |
| TR201904270T4 (tr) | Tanımlı koşullar altında insan pluripotent kök hücrelerinin hematoendotelyal farklılaşması için yöntemler ve materyaller. | |
| MX373383B (es) | Metodo para preparar rebaudiosido m mediante el uso de un metodo con enzima. | |
| CY1122612T1 (el) | Μεθοδος | |
| WO2017100403A8 (en) | Human t cell derived from t cell-derived induced pluripotent stem cell and methods of making and using | |
| MX375842B (es) | Mejoramiento de señales de referencia para una celula compartida. | |
| MX376437B (es) | Uso de hígado descelularizado por perfusión para recelularización de células de islote. | |
| MX2021001859A (es) | Medio de cultivo celular libre de suero. | |
| MX2022009653A (es) | Receptores del antigeno quimerico que seleccionan el antigeno para la maduracion de las celulas b. | |
| EA201591926A1 (ru) | Способ многоцветной проточной цитометрии для идентификации популяции клеток, в частности мезенхимальных стволовых клеток | |
| BR112013002811A8 (pt) | meios básicos simplificados para cultura celular pluripotente de humano | |
| MX375786B (es) | Biosintesis microbiana de ergotioneina. | |
| MX2015005627A (es) | Sistemas y metodos para conversion de profundidad de datos sismicos 3d utlizando redes neuronales artificiales. | |
| GB2525693A (en) | Methods and systems for transmitting and receiving data through tunnel groups | |
| WO2019086959A3 (en) | Compositions and methods for improved gamete viability and function | |
| CY1122798T1 (el) | Μεθοδος για τη διαφοροποιηση του πλειοδυναμου βλαστικου κυτταρου επαγομενη απο το μεσεγχυματικο βλαστικο κυτταρο σε χονδροκυτταρο | |
| SV2016005288A (es) | Mã‰todos y aparato para la coordinaciã“n de la selecciã“n del sistema entre un conjunto de nodos | |
| WO2016106192A3 (en) | Methods of culturing a mammalian cell | |
| DOP2016000220A (es) | PROTEÍNAS DE FUSIÓN TATk-CDKL5, COMPOSICIONES, FORMULACIONES Y USO DE ESTAS. | |
| EA201791233A1 (ru) | Материал стволовых клеток и способ его получения | |
| EP4462437A3 (en) | Genomic data analysis system and method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (FR) ; FONDATION IMAGINE - INSTITUT DES MALADIES GENETIQUES (FR) ; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) ; UNIVERSITE DE PARIS (FR) |
|
| B25D | Requested change of name of applicant approved |
Owner name: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (FR) ; FONDATION IMAGINE - INSTITUT DES MALADIES GENETIQUES (FR) ; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) ; UNIVERSITE PARIS CITE (FR) |
|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |